828-81-9

Basic information

• Product Name: 2-AMINO-5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOLE
• Synonyms: VITAS-BB TBB000090;IFLAB-BB F1386-0067;5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOL-2-AMINE;5-(2-CHLORO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE;2-AMINO-5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOLE;1,3,4-Thiadiazol-2-aMine, 5-(2-chlorophenyl)-;5-(2-Chlorophenyl)
• CAS NO: 828-81-9
• Molecular Formula: C₈H₆ClN₃S
• Molecular Weight: 211.67
• Mol File: 828-81-9.mol
• Article Data: 47

Chemical Properties

• Melting Point: 192-195 °C
• Boiling Point: 393.8±44.0 °C(Predicted)
• Appearance: /
• Density: 1.461±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.28±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOLE(828-81-9)
• EPA Substance Registry System: 2-AMINO-5-(2-CHLOROPHENYL)-1,3,4-THIADIAZOLE(828-81-9)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 828-81-9(Hazardous Substances Data)

Usage

General Description

2-Amino-5-(2-chlorophenyl)-1,3,4-thiadiazole is a synthetic, organic compound known for its complex structure with multiple heterocyclic rings including a thiadiazole ring, aromatic chlorophenyl ring and an amino group. The heterocyclic thiadiazole group features sulfur and nitrogen atoms, contributing to its chemical reactivity. This chemical is typically used in the area of medicinal chemistry and pharmaceuticals, where it has potential use as a bioactive agent due to its possible anti-microbial, anti-inflammatory, anti-tubercular, and anti-cancer properties. However, its toxicity and full profile of biological activity are not fully explored, and it is not widely available for commercial use.

Upstream product

• 79-19-6 thiosemicarbazide 
• 118-91-2 ortho-chlorobenzoic acid 
• 5814-05-1 2-chlorobenzoylhydrazide 
• 2290-65-5 trimethylsilyl isothiocyanate 
• 333-20-0 potassium thioacyanate 
• 107135-19-3 N’-(2-chlorobenzylidene)-4-methylbenzenesulfonohydrazide 
• 89-98-5 2-chloro-benzaldehyde 
• 610-96-8 methyl chlorobenzoate 
• 830-86-4 4-(o-chloro)benzoylthiosemicarbazide 
• 5706-78-5 2-chlorobenzaldehyde thiosemicarbazone 

Downstream Products

• 170950-31-9 [5-(2-Chloro-phenyl)-[1,3,4]thiadiazol-2-yl]-thiourea 
• 391863-73-3 C₁₂H₁₀ClN₃OS 
• 1236182-57-2 9-(4-methoxy)-3-(2'-chlorophenyl)-5H,13aH-quinolino[3,2-f][1,2,4]triazolo[4,3-b][1,2,4]triazepine 
• 674768-68-4 2-(2-chloro-phenyl)-7-phenyl-6,7-dihydro-[1,3,4]thiadiazolo[3,2-a][1,3,5]triazine-5-thione 

Relevant articles and documents

N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound

The invention belongs to the technical field of medicines, relates to a compound with antitumor activity and a specific chemical structure, and in particular relates to an N-((6, 7-dimethoxyquinoline-4-yl) oxy) methyl)-N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound and a preparation method and an application thereof. The structural general formula of the compound is shown in the specification, wherein an R group is mono-substituted or double-substituted phenyl, fluorophenyl, chlorphenyl, bromophenyl, benzyl, benzyloxy, benzene nitro or trifluoromethyl substituted at 2-position, 3-position or 4-position. Pharmacological studies show that the compound provided by the invention has a relatively remarkable proliferation inhibition effect on HER-2 positive breast cancer cells SK-Br-3, the effect is obviously superior to that of HER-2 negative breast cancer cells MCF-7, the compound can be used for preparing antitumor drugs, and a new way is opened up for deep research and development of tumor drugs in the future. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Synthesis, docking, and biological evaluation of thiazolidinone derivatives against hepatitis C virus genotype 4a

Hepatitis C virus (HCV) genotype 4a (GT4a) is prevalent in Egypt. It did not gain the necessary scientific focus despite its high resistance. Since the crystal structure NS5B (RNA-dependent RNA polymerase) of HCV GT4a has not been resolved until now, homology modeling was conducted to build and validate the 3D model of the enzyme. Ligand binding sites including the allosteric thumb II pocket were detected and used in lead optimization. Sixty new 4-thiazolidinone derivatives have been virtually designed and docked into thumb II site of HCV NS5B GT4a using rigid docking approach. Eighteen compounds (7a–r) that show good docking scores were synthesized and tested in vitro against NS5B GT4a. Compounds 7b and 7n showed the best inhibitory activity (IC50 = 0.338 and 0.342 μM, respectively). Compounds 7a, 7b, 7c, 7d, 7k, 7n, 7q, and 7r that have IC50 values less than 2 μM were assessed for cellular anti-HCV GT4a activity using human hepatoma cell line (Huh 7.5). The percentages of viral growth inhibition are between 79.67 and 94.77%. Compound 7b is the most active in the in vitro and cellular assays and could be considered a potential new lead for future anti-HCV studies. [Figure not available: see fulltext.]

Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents

New indole-tethered [1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one (8a-j) and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids (9a-e) were synthesized using [4+2] cycloaddition reactions of functionalized 1,3-diazabuta-1,3-dienes with indole-ketenes. All molecul